Slingshot members are tracking this event:

FDA Priority Review date for Venetoclax Set mid-2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details After being granted priority review and accepting AbbVie's NDA submission for venetoclax, the FDA will make a decisions on venetoclax in mid 2016.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 11, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Venetoclax, Chronic Lymphocytic Leukemia, Bcl-2 Inhibitor, 17p Deletion, B-cell Lymphoma-2